SLC5A2 and type 2 diabetes mellitus: In clinical trials involving patients diagnosed with T2DM or obesity without diabetes, SGLT2 inhibitor-induced glycosuria led to a decrease in plasma glucose and insulin levels while simultaneously increasing both fasting and post-meal glucagon concentrations.